c-Myb-mediated inhibition of miR-601 in facilitating malignance of osteosarcoma via augmentation of PKMYT1.
Bone Neoplasms
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Computational Biology
Gene Expression Regulation, Neoplastic
Humans
Membrane Proteins
/ metabolism
MicroRNAs
/ genetics
Osteosarcoma
/ genetics
Prognosis
Protein Serine-Threonine Kinases
/ genetics
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins c-myb
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 04 2022
23 04 2022
Historique:
received:
07
10
2021
accepted:
12
04
2022
entrez:
24
4
2022
pubmed:
25
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
The crosstalk between osteosarcoma (OS) development and abnormally expressed microRNA (miR)-601 is not explored explicitly. Here, we identified the downregulated miR-601 in osteosarcoma (OS) through a comprehensive bioinformatics analysis of GEO Datasets. The results indicated that miR-601 was downregulated in both OS cells and tissues. The OS patients with reduced expression of miR-601 displayed worse prognosis. The results of in vitro and in vivo assay revealed that elevated miR-601 inhibited the proliferative, migratory and invasive capacities in OS cells. Mechanically, miR-601 exerted its function via targeting oncogene protein kinase membrane associated tyrosine/threonine 1 (PKMYT1) at post-transcriptional level. Moreover, miR-601 was attenuated by c-Myb at transcriptional level. Taken together, our studies reveal that miR-601 is a suppressive gene negatively correlated with malignancy of OS.
Identifiants
pubmed: 35461324
doi: 10.1038/s41598-022-10684-0
pii: 10.1038/s41598-022-10684-0
pmc: PMC9035158
doi:
Substances chimiques
MIRN601 microRNA, human
0
MYB protein, human
0
Membrane Proteins
0
MicroRNAs
0
Proto-Oncogene Proteins c-myb
0
Protein-Tyrosine Kinases
EC 2.7.10.1
PKMYT1 protein, human
EC 2.7.11.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6692Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
J Hematol Oncol. 2020 Sep 21;13(1):126
pubmed: 32958072
Cell Signal. 2019 Jul;59:171-181
pubmed: 30953699
Crit Rev Biochem Mol Biol. 2016 May-Jun;51(3):121-34
pubmed: 26628006
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
Molecules. 2017 Nov 23;22(12):
pubmed: 29168755
Oncogene. 2009 Nov 19;28(46):4065-74
pubmed: 19734943
Onco Targets Ther. 2020 Aug 04;13:7747-7757
pubmed: 32801781
Ann Transl Med. 2018 Nov;6(22):443
pubmed: 30596073
Cancer Biother Radiopharm. 2019 Dec;34(10):605-613
pubmed: 31674804
Eur Rev Med Pharmacol Sci. 2019 May;23(10):4210-4219
pubmed: 31173292
Cancer Res. 2019 Dec 1;79(23):5971-5985
pubmed: 31594837
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313
Cancer Manag Res. 2019 Aug 19;11:7813-7824
pubmed: 31695486
Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
pubmed: 20943636
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Cancer Gene Ther. 2019 Jul;26(7-8):179-182
pubmed: 30905966
Exp Cell Res. 2017 Sep 15;358(2):209-216
pubmed: 28648520
Cancer Biomark. 2017 Dec 12;21(1):135-144
pubmed: 29060932
Gene. 2020 Jun 20;744:144608
pubmed: 32234541
Cancer Biol Med. 2020 Aug 15;17(3):782-794
pubmed: 32944406
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
Prog Cell Cycle Res. 1997;3:233-40
pubmed: 9552418
J Biol Chem. 2015 Jan 23;290(4):2198-212
pubmed: 25477524
Biochem Biophys Res Commun. 2017 Jan 29;483(1):638-644
pubmed: 27993677
Cancer Invest. 2019;37(1):46-65
pubmed: 30599775
Annu Rev Pathol. 2009;4:199-227
pubmed: 18817506
Oncol Rep. 2018 Feb;39(2):545-553
pubmed: 29207178
Biomed Pharmacother. 2016 Apr;79:247-53
pubmed: 27044835
Vet Sci. 2019 May 25;6(2):
pubmed: 31130627
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5259-5266
pubmed: 32495859
Hum Cell. 2018 Oct;31(4):292-299
pubmed: 29907935
Nat Rev Drug Discov. 2020 Mar;19(3):157
pubmed: 32127662
PLoS One. 2012;7(9):e44398
pubmed: 22970209
Int J Mol Sci. 2020 Sep 19;21(18):
pubmed: 32961800
Theranostics. 2019 Jul 9;9(18):5298-5314
pubmed: 31410216
Oncol Rep. 2018 Jun;39(6):2829-2836
pubmed: 29658598
Cancer Res. 2019 Apr 1;79(7):1398-1412
pubmed: 30563888